Ovid Therapeutics Inc. stock is down -7.38% since 30 days ago. The next earnings date is Mar 11, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 28.57% of the previous 6 February’s closed higher than January.
Ovid Therapeutics Inc. develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome. OV329, a GABA aminotransferase inhibitor, and OV350, a small molecule for treating epilepsies.
Unlock Exclusive Market Insights! Receive timely updates on market developments. Sign up & stay informed!